Page last updated: 2024-12-06

10-camphorsulfonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

You are likely referring to **10-camphorsulfonic acid**, also known as **camphorsulfonic acid** or **CSA**. This is an organic compound used as a chiral reagent in organic synthesis. It's not a specific compound like 10-camphorsulfonic acid, rather it's a generic term referring to a type of sulfonic acid.

Here's why it's important in research:

**1. Chiral Catalyst:**

* **Enantioselectivity:** Camphorsulfonic acid is a chiral compound, meaning it exists in two mirror-image forms (enantiomers). This property allows it to act as a chiral catalyst, promoting reactions that favor the formation of one enantiomer over the other.
* **Chirality in Pharmaceuticals:** Many pharmaceuticals are chiral, and only one enantiomer is often responsible for the desired therapeutic effect. Using camphorsulfonic acid as a catalyst enables the synthesis of specific enantiomers, improving the efficacy and safety of drug molecules.

**2. Protecting Group:**

* **Protecting functionality:** Camphorsulfonic acid can be used to temporarily protect specific functional groups in organic molecules during synthesis. This helps avoid unwanted side reactions while the desired transformation takes place.

**3. Acid Catalyst:**

* **Broad Application:** Like other sulfonic acids, camphorsulfonic acid acts as a strong Brønsted acid catalyst, driving a wide range of reactions, including esterification, acetal formation, and dehydration.

**Examples of Research Applications:**

* **Asymmetric Catalysis:** Camphorsulfonic acid is a key component in many asymmetric reactions, such as Diels-Alder reactions, Friedel-Crafts alkylations, and aldol condensations.
* **Organic Synthesis:** It is widely used in the synthesis of complex organic molecules, including natural products and pharmaceuticals.
* **Materials Science:** Its ability to influence chirality has led to research in developing chiral materials with specific properties.

**Note:** There are different variations of camphorsulfonic acid, such as (+)-camphorsulfonic acid and (-)-camphorsulfonic acid, which differ in their enantiomeric configuration. Choosing the appropriate enantiomer is crucial for achieving desired enantioselectivity in reactions.

10-camphorsulfonic acid: solucampher refers to piperazine salt; RN given refers to parent cpd; structure in Negwer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

camphorsulfonic acid : A sulfonic acid containing the camphorsulfonate anion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID18462
CHEBI ID55379
SCHEMBL ID3604
MeSH IDM0049699

Synonyms (92)

Synonym
AC-12238
5872-08-2
dl-camphorsulfonic acid
bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1s)-
{7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl}methanesulfonic acid
EN300-20050
dl-10-camphorsulfonic acid
d-10-camphorsulfonic acid
2-oxobornane-10-sulphonic acid
10-bornanesulfonic acid, 2-oxo-, (1s,4r)-(+)-
camphorsulfonic acid
camphersulfosaeure
CHEBI:55379
10-csa
(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic acid
(+)-10-camphorsulfonic acid
(+/-)-10-camphorsulfonic acid
(+/-)-csa
AKOS000267736
FT-0655494
(7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl)methanesulfonic acid
d-camphor-10-sulfonic acid
10-camphorsulfonic acid
FT-0625379
FT-0624350
(7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonic acid
d-camphor sulfonic acid
AM81424
AKOS016039123
SCHEMBL3604
(+/-)-camphorsulfonic acid
(+/-)-camphor-10-sulfonic acid
(-) camphorsulfonic acid
(+)-camphorsulfonic acid
10-camphorsulphonic acid
(+)-10camphorsulfonic acid
racemic camphor-10-sulfonic acid
(+) camphorsulfonic acid
1r-(-)-camphorsulfonic acid
(+/-) camphor sulfonic acid
(+)-camphor-10-sulfonic acid
camphor-10-sulphonic acid
l-10-(-)-camphor sulfonic acid
(rac)-camphorsulfonic acid
(+)camphorsulfonic acid
(+/-) 10-camphor sulphonic acid
(+/-)-10-camphorsulphonic acid
camphorsulphonic acid
10-camphor sulfonic acid
(+)camphor sulfonic acid
camphor sulfonic acid
(+/-)-10-camphor sulfonic acid
(-)camphorsulfonic acid
(-/+)-10-camphorsulfonic acid
camphor sulphonic acid
(-)-10-camphorsulphonic acid
(+/-) camphorsulfonic acid
dl-camphor sulfonic acid
camphor-10-sulfonic acid, (+)-
(+)-.beta.-camphorsulfonic acid
.beta.-camphorsulfonic acid, (+)-
(+)-camphor-10-sulfonic acid (.beta.)
(+)-camphor-10-sulphonic acid
dextro-10-camphorsulfonic acid
camsylate
(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic acid, (1s,4r)- #
camphostyl
camphor-.omega.-sulfonic acid, (+)-
7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonic acid, (1s,4r)-
STL490650
J-520408
CS-D1796
F2124-0036
CS-W001192
sr-01000944696
SR-01000944696-1
camphersulfonsaure
l-(+)-camphorsulfonic acid
61380-66-3
7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonic acid
A923863
(7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonicacid
DTXSID60863113
Q414283
CS-W012934
BS-17109
l-(+)-camphorsulfonicacid
P20541
{7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-ylmethanesulfonic acid
(1s)-(+)-camphor-10-sulfonic acid(dry wt.),water
(7,7-dimethyl-2-oxobicyclo[2.2.1]-heptan-1-yl)methanesulfonic acid
camphor-10-sulfonic acid ( beta )

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"00 mg/mL), for 90 days caused neither test-item-related mortality nor adverse clinical signs."( D-10-camphorsulfonic acid: Safety evaluation.
Appl, Á; Dahms, I; Esdaile, DJ; Fehr, M; Naumann, S; Schulz, M,
)
0.85

Compound-Compound Interactions

ExcerptReferenceRelevance
"The enantiomeric separation of a series of basic pharmaceuticals (beta-blockers, local anesthetics, sympathomimetics) has been investigated in nonaqueous capillary electrophoresis (NACE) systems using heptakis(2,3-di-O-methyl-6-O-sulfo)-beta-cyclodextrin (HDMS-beta-CD) in combination with potassium camphorsulfonate (camphorSO3-)."( Enantiomeric separation of basic compounds using heptakis(2,3-di-O-methyl-6-O-sulfo)-beta-cyclodextrin in combination with potassium camphorsulfonate in nonaqueous capillary electrophoresis: optimization by means of an experimental design.
Chiap, P; Crommen, J; Dewé, W; Fillet, M; Hubert, P; Servais, AC, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organosulfonic acidAn organic derivative of sulfonic acid in which the sulfo group is linked directly to carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (12.00)18.7374
1990's2 (8.00)18.2507
2000's7 (28.00)29.6817
2010's11 (44.00)24.3611
2020's2 (8.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.52 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index73.92 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]